Patents by Inventor Timothy Joseph MCAFOOS

Timothy Joseph MCAFOOS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS
    Publication number: 20230312588
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
    Type: Application
    Filed: March 13, 2023
    Publication date: October 5, 2023
    Inventors: Kang LE, Michael J. SOTH, Philip JONES, Jason Bryant CROSS, Timothy Joseph MCAFOOS
  • IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS
    Publication number: 20230295173
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
    Type: Application
    Filed: March 13, 2023
    Publication date: September 21, 2023
    Inventors: Kang LE, Michael J. SOTH, Philip JONES, Jason Bryant CROSS, Timothy Joseph MCAFOOS
  • Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases
    Patent number: 11725008
    Abstract: The present invention relates to ethanediamine-heterocycle compounds that are able to act as inhibitors of PRMTs (protein arginine methyltransferases) for treating cancer and other diseases mediated by PRMTs.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: August 15, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Joseph McAfoos
  • ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES
    Publication number: 20230027126
    Abstract: The present invention relates to ethanediamine-heterocycle compounds that are able to act as inhibitors of PRMTs (protein arginine methyltransferases) for treating cancer and other diseases mediated by PRMTs.
    Type: Application
    Filed: May 4, 2021
    Publication date: January 26, 2023
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy Joseph MCAFOOS
  • IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS
    Publication number: 20230008047
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
    Type: Application
    Filed: May 21, 2021
    Publication date: January 12, 2023
    Inventors: Kang LE, Michael J. SOTH, Philip JONES, Jason Bryant CROSS, Christopher L. CARROLL, Timothy Joseph MCAFOOS, Pijus Kumar MANDAL
  • Imidazopiperazine inhibitors of transcription activating proteins
    Patent number: 11058688
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: July 13, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Kang Le, Michael J. Soth, Philip Jones, Jason Bryant Cross, Christopher L. Carroll, Timothy Joseph McAfoos, Pijus Kumar Mandal
  • Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases
    Patent number: 11028083
    Abstract: The present invention relates to ethanediamine-heterocycle compounds that are able to act as inhibitors of PRMTs (protein arginine methyltransferases) for treating cancer and other diseases mediated by PRMTs.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: June 8, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Joseph McAfoos
  • Imidazopiperazinone inhibitors of transcription activating proteins
    Patent number: 10899769
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: January 26, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Kang Le, Michael J. Soth, Gang Liu, Philip Jones, Jason Bryant Cross, Timothy Joseph Mcafoos, Christopher L. Carroll, Richard T. Lewis
  • IMIDAZOPIPERAZINONE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS
    Publication number: 20190308978
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
    Type: Application
    Filed: April 8, 2019
    Publication date: October 10, 2019
    Inventors: Kang LE, Michael J. SOTH, Gang LIU, Philip JONES, Jason Bryant CROSS, Timothy Joseph MCAFOOS, Christopher L. CARROLL, Richard T. LEWIS
  • IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS
    Publication number: 20190298729
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
    Type: Application
    Filed: March 29, 2019
    Publication date: October 3, 2019
    Inventors: Kang LE, Michael J. SOTH, Philip JONES, Jason Bryant CROSS, Christopher L. CARROLL, Timothy Joseph MCAFOOS, Pijus Kumar MANDAL
  • ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES
    Publication number: 20190270739
    Abstract: The present invention relates to ethanediamine-heterocycle compounds that are able to act as inhibitors of PRMTs (protein arginine methyltransferases) for treating cancer and other diseases mediated by PRMTs.
    Type: Application
    Filed: March 1, 2019
    Publication date: September 5, 2019
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy Joseph MCAFOOS